insights_auto
Why is 6160 up ၄.၃၆%?
Dive Deeperchevron_right
6160:HKG
BeOne Medicines AG
၂၂၅.၀၀ HK$
arrow_upward
+၄.၃၆%(+၉.၄၀) 1D
အောက် ၁၆, GMT+၈ ၁၆:၀၈:၁၄ · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 6160...
Open
၂၂၄.၈၀ HK$
High
၂၃၀.၂၀ HK$
Low
၂၂၁.၈၀ HK$
Mkt. cap
ဋေ ၃.၅၆ သ
Avg. vol.
၂.၉၃ သန်း
Volume
၄.၄၁ သန်း
P/E ratio
၆၅.၆၇
52-wk high
၂၃၅.၆၀ HK$
52-wk low
၁၅၃.၀၀ HK$
EPS
၃.၄၃ HK$
Shares outstanding
၁၄၂.၆၄ ဋေ
No. of employees
၁ သောင်း
Open
၂၂၄.၈၀ HK$
High
၂၃၀.၂၀ HK$
Low
၂၂၁.၈၀ HK$
Mkt. cap
ဋေ ၃.၅၆ သ
Avg. vol.
၂.၉၃ သန်း
Volume
၄.၄၁ သန်း
P/E ratio
၆၅.၆၇
52-wk high
၂၃၅.၆၀ HK$
52-wk low
၁၅၃.၀၀ HK$
EPS
၃.၄၃ HK$
Shares outstanding
၁၄၂.၆၄ ဋေ
No. of employees
၁ သောင်း
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၃ ရက်
TB Alternative Assets Ltd. Makes New $5.42 Million Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees၁.၂ သောင်း
Founded၂၀၁၀ အောက် ၂၈
Headquarters-
Sector-
Websitebeonemedicines.com